Sign In Registration

Home
Registration

Registration for the Zyprexa Relprevv Clinical Resource Hub

Title

Specialty

First Name

Last Name

Email

AHPRA Number

Country

Zyprexa Website Terms of Use

Zyprexa Privacy Policy

Contact Us 1800 210 564 custserv@pharmaco.com.au

Prior to prescribing or for any questions related to Zyprexa Relprevv administration or use, please carefully review the Product Information accessible at the TGA website www.tga.gov.au/resources/artg/143658 or contact Pharmaco Medicines Information: 1800 210 564. WARNING: The potential for signs and symptoms of sedation and/or delirium consistent with olanzapine overdose exists after every injection of ZYPREXA RELPREVV. ZYPREXA RELPREVV should be administered by appropriately qualified health professionals in a healthcare facility with access to emergency services for management of olanzapine overdose. Healthcare professionals who prescribe or administer ZYPREXA RELPREVV should be aware of this potential risk and the consequent need to monitor patients for at least two hours after each injection. The two hour period should be extended as clinically appropriate for patients who exhibit any potential signs or symptoms of a post-injection syndrome event. See Section 4.4, in the full PI. PBS information: Authority required (Streamlined for Schizophrenia) ZYPREXA RELPREVV is under licence of CHEPLAPHARM Schweiz GmbH, Switzerland.

Copyright © 2026 Pharmaco Pharmaceuticals AU

Distributed in Australia by Pharmaco (Australia) Ltd, Chatswood NSW 2067. Last updated 22nd September 2025. PHAA371

A division of

Sign In
Registration